The U.S. Trade Representative named Vietnam as a Priority Foreign Country in its latest Special 301 Report, calling out pricing and intellectual property issues affecting biopharma and med-tech. The annual report also relisted multiple countries, including China and India, on a Priority Watch List and added countries to a broader Watch List. For life sciences companies with manufacturing or commercial footprints in the region, the designation increases scrutiny around IP enforcement and could influence how sponsors structure market access and pricing strategies. The decision is notable because it marks the first time in 13 years the USTR selected Vietnam as the highest-priority category, elevating the probability of follow-on trade actions.